[{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"}]